Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

@article{Astrup2008EffectOT,
  title={Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial},
  author={Arne Astrup and Sten Madsbad and Leif Breum and Thomas Jon Jensen and Jens Peter Kroustrup and Thomas Meinert Larsen},
  journal={The Lancet},
  year={2008},
  volume={372},
  pages={1906-1913}
}
Multicenter, placebo-controlled trial of lorcaserin for weight management.
TLDR
In conjunction with behavioral modification, lorcaserin was associated with significant weight loss and improved maintenance of weight loss, as compared with placebo.
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
TLDR
TE has a pronounced effect on appetite sensations and a slight effect on energy expenditure at night—both effects can contribute to the strong weight-reducing effect of TE.
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects
TLDR
Diethylpropion plus diet produced sustained and clinically significant weight loss over 1 year and seems to be safe in relation to cardiovascular and psychiatric aspects in a well-selected population.
The Effect of Tesofensine on appetite
TLDR
It is postulate that enhanced satiety is involved in early weight loss, and the attenuated effect on appetite seen after 24 weeks is due to a counteracting effect in the weight reduced state or whether the appetite suppressing effect of TE per se diminishes over time is still unclear.
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
TLDR
Tesomet was welltolerated, did not affect heart rate or blood pressure, and resulted in significant reductions in body weight compared to placebo in adults with hypothalamic obesity.
Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
TLDR
All subscales of the IWQOL‐Lite and SF‐36 were significantly improved with liraglutide 3.0 mg and theSF‐36 PCS scores.
The Effect of Tesofensine on Appetite Sensations
TLDR
It is postulate that enhanced satiety is involved in early weight loss, whether the attenuated effect on appetite seen after 24 weeks is due to a counteracting effect in the weight reduced state or whether the appetite suppressing effect of TE per se diminishes over time.
Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
TLDR
Although reduction in BMI accounted for the majority of improvements in obesity-specific and physical HRQOL, decrease in depressive symptoms was also a significant mediator, highlighting the predominance of weight reduction as a key factor in improvingHRQOL in obesity.
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
TLDR
One of the strategies for long-term obesity control is that anti-obesity medications should be tailored for specific patients depending on their chronic conditions, comorbidities, and preferences.
...
...

References

SHOWING 1-10 OF 22 REFERENCES
The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
TLDR
The weight reducing effect of sibutramine in humans is caused by a dual mechanism: reduction of energy intake by increasing satiety and decreasing hunger and prevention of the decline in EE that follows weight loss.
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
TLDR
Six-week treatment with sibutramine appears to be efficacious, tolerable and safe in this high-risk population of overweight/obese subjects with an increased risk of cardiovascular disease, for whom sibutanine is usually contraindicated.
Thermogenic effects of sibutramine in humans.
TLDR
Sibutramine caused a significant increase in both EE and satiety, which may both contribute to its weight-reducing properties.
Meta-Analysis: Pharmacologic Treatment of Obesity
TLDR
This review of 79 clinical trials involving diet plus the obesity drugs sibutramine, orlistat, fluoxetine, sertraline, bupropion, topiramate, or zonisamide shows that these medications can lead to modest weight reductions of approximately 5 kg or less at 1 year.
Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients
TLDR
In overweight/obese patients, 20 mg/day rimonabant produced weight loss and significant improvements in multiple cardiometabolic risk factors such as waist circumference, A1C, HDL cholesterol, and triglycerides, and ANCOVA suggested that 45–57% of the effect of rim onabant could not be explained by the observed weight loss.
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
TLDR
Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
TLDR
To determine whether weight loss and metabolic effects of the selective cannabinoid type 1 receptor antagonist rimonabant reduces progression of coronary disease in patients with abdominal obesity and the metabolic syndrome, the study failed to show an effect on disease progression.
...
...